Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials
- 1 April 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (4), 583-592
- https://doi.org/10.1158/1940-6207.capr-11-0482
Abstract
High body mass index (BMI) has been associated with an increased risk for breast cancer among postmenopausal women. However, the relationship between BMI and breast cancer risk in premenopausal women has remained unclear. Data from two large prevention trials conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) were used to explore the relationship between baseline BMI and breast cancer risk. The analyses included 12,243 participants with 253 invasive breast cancer events from the Breast Cancer Prevention Trial (P-1) and 19,488 participants with 557 events from the Study of Tamoxifen and Raloxifene (STAR). Both studies enrolled high-risk women (Gail score ≥ 1.66) with no breast cancer history. Women in P-1 were pre- and postmenopausal, whereas women in STAR (P-2) were all postmenopausal at entry. Using Cox proportional hazards regression, we found slight but nonsignificant increased risks of invasive breast cancer among overweight and obese postmenopausal participants in STAR and P-1. Among premenopausal participants, an increased risk of invasive breast cancer was significantly associated with higher BMI (P = 0.01). Compared with BMI less than 25, adjusted HRs for premenopausal women were 1.59 for BMI 25 to 29.9 and 1.70 for BMI 30 or more. Our investigation among annually screened, high-risk participants in randomized, breast cancer chemoprevention trials showed that higher levels of BMI were significantly associated with increased breast cancer risk in premenopausal women older than 35 years, but not postmenopausal women. Cancer Prev Res; 5(4); 583–92. ©2012 AACR.Other Versions
This publication has 37 references indexed in Scilit:
- Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention TrialCancer Prevention Research, 2011
- Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Nonobese Women at High Risk for Breast Cancer: Feasibility DataCancer Epidemiology, Biomarkers & Prevention, 2011
- Body Fat Distribution and Risk of Premenopausal Breast Cancer in the Nurses' Health Study IIJNCI Journal of the National Cancer Institute, 2010
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- A Case-Control Study of Body Mass Index and Breast Cancer Risk in White and African-American WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- Obesity and Cancer: The Role of Dysfunctional Adipose TissueCancer Epidemiology, Biomarkers & Prevention, 2009
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)International Journal of Cancer, 2004
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- The role of oestrogens and progestagens in the epidemiology and prevention of breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988